Search clinical trials for: Humira®

Total 20276 results

Alcon Research

Completed

Visual Assessment of DAILIES® AquaComfort Plus® for Astigmatism as Compared to 1-DAY ACUVUE® MOIST® for Astigmatism

Astigmatism
Ulthera, Inc

Completed

Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers

Skin Laxity

United States
Ulthera, Inc

Completed

Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea

Rosacea | Erythematotelangiectatic Rosacea

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
University of Michigan

Recruiting

Effectiveness of Aquamin® in Mitigating Halitosis

Healthy | Halitosis

United States
Wright State University
Wake Forest University Health Sciences; Stanford University

Withdrawn

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
AbbVie

Completed

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom
Centocor Ortho Biotech Services, L.L.C.
Schering-Plough

Completed

RESTART C0168Z05 Rheumatoid Arthritis Study

Rheumatoid Arthritis

United States, United Kingdom, Spain, Israel, Finland, Canada, France, Austria, Germany, Netherlands
British Columbia Cancer Agency
Genomic Health®, Inc.

Unknown

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

Breast Cancer

Canada
Applied Molecular Transport

Completed

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Ulcerative Colitis

Georgia, Netherlands, Poland, Ukraine
Ology Bioservices
Pharm-Olam, LLC; Chemical, Biological, Radiological, and Nuclear Medical

Withdrawn

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) (COMBAAT)

Mild to Moderate COVID-19
University of Oxford
Wellcome Trust; Department of Health, United Kingdom; 180 Therapeutics LP

Completed

Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD)

Dupuytren's Disease

United Kingdom, Netherlands
Jonathan Graf
AbbVie; American College of Rheumatology Research and Education Foundation

Completed

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

Cardiovascular Disease | Rheumatoid Arthritis

United States
Lundquist Institute for Biomedical Innovation at...

Completed

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Mucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI

United States
Innovaderm Research Inc.
Abbott; Montreal Heart Institute

Completed

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Psoriasis | Coronary Atherosclerosis | Vascular Inflammation

Canada
Regionshospitalet Silkeborg
Medtronic - MITG; Central Denmark Region; Abbott

Completed

Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (INTASAH)

Enterocolitis | Spondyloarthritis

Denmark
AbbVie

Completed

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Canada, Czechia, Hungary, Israel, Japan, New Zealand, Poland, Slovakia, Spain, United Kingdom
AbbVie

Completed

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS)

Hidradenitis Suppurativa (HS)

United States, Belgium, Canada, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Sweden, Turkey, United Kingdom
Cinnagen

Completed

A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects

Bioequivalence | Phase 1

Iran, Islamic Republic of
University of Alberta
Abbott

Withdrawn

Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

Crohn's Disease | Spondyloarthritis

Canada
LG Life Sciences

Completed

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

Healthy Subjects
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Meningitis | Meningococcal Disease

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Medical University of Graz

Recruiting

Evaluation of Minimal Invasive Glaucoma Surgery

Glaucoma

Austria
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Hospital Universitario La Paz

Unknown

Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors

Severe Haemophilia A With Inhibitors

Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation

Menopause
NYU Langone Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

Cystinuria

United States
Biose

Completed

Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation (COMPRIGEL)

Candidiasis, Vulvovaginal

France
Francisco Selva

Withdrawn

Effects of Magnetic Tape Over Ankle Dorsiflexion in Patients With Low Back Pain

Low Back Pain

Spain
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER I)

Hidradenitis Suppurativa (HS)
Teva Neuroscience, Inc.

Completed

A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

Multiple Sclerosis
Astellas Pharma Europe Ltd.

Completed

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder Overactive

Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (PIONEER II)

Hidradenitis Suppurativa (HS)
AbbVie

Completed

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Rheumatoid Arthritis
AbbVie

Completed

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis (GPP) | Adalimumab | Japanese
Abbott

Completed

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Crohn's Disease

United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Africa, Spain, Sweden, United Kingdom
Abbott

Completed

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis (ReAct)

Rheumatoid Arthritis
Alvotech Swiss AG

Completed

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers (ALVOPAD)

Healthy Volunteers

Australia
Amgen

Completed

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Chronic Kidney Disease | Kidney Disease
University of Malaya

Completed

Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia

Trigeminal Neuralgia

Malaysia
Aesculap AG

Active, not recruiting

Post Market Clinical Follow-Up of Plasmafit® Cup

Total Hip Arthroplasty

Germany
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

Hungary, Serbia, Georgia, Russian Federation, Slovakia, Czechia, Bulgaria, Moldova, Republic of, Poland
Coherus Biosciences, Inc.

Completed

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)

Plaque Psoriasis

United States, Canada, Bulgaria, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Republic of, Poland, Russian Federation, Slovakia, South Africa, Ukraine
AbbVie
Raffeiner GmbH

Completed

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (Adherence)

Rheumatoid Arthritis | Plaque Psoriasis | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis | Crohn´s Disease
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

Crohn's Disease
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Intestinal Behçet's Disease

Japan
Abbott
Eisai Limited

Completed

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
AbbVie

Completed

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Romania, Slovakia, Spain, Switzerland, Ukraine, United Kingdom

Search clinical trials for: Humira®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations